Zymeworks Announces Strategic Collaboration With Eli Lilly and Company Subsidiary ImClone Systems To Develop Bi-specific Antibodies Using Zymeworks' Azymetric™ Platform
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks’ proprietary Azymetric™ platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.
Help employers find you! Check out all the jobs and post your resume.